Search research articles
Contact Us
Filters
Showing results (131-140 of 159) with videos related to
Page
of 16
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
September 24, 2011
Effect of hepatic cytochrome P450 (P450) oxidoreductase deficiency on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct formation in P450 reductase conditional null mice
Volker M Arlt, Rajinder Singh, Marie Stiborová, et al.
Cancer Research
|
May 6, 2004
Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines
Ruth L Stephen, Mattias C U Gustafsson, Morag Jarvis, et al.
The Biochemical Journal
|
March 3, 2004
Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite
Jack U Flanagan, Jean-Didier Maréchal, Richard Ward, et al.
Genes, Chromosomes & Cancer
|
October 20, 2005
Chromosomal changes in colorectal adenomas: relationship to gene mutations and potential for clinical utility
Amy Leslie, Arlene Stewart, David U Baty, et al.
Archives of Toxicology
|
January 26, 2018
Cytochrome b <sub>5</sub> impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b <sub>5</sub> /P450 reductase null (HBRN) mice
Lindsay Reed, Iveta Mrizova, Frantisek Barta, et al.
Toxicology
|
February 18, 2014
Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions
Marie Stiborová, Michaela Moserová, Věra Černá, et al.
Cancer Research
|
April 5, 2005
Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols
Volker M Arlt, Marie Stiborova, Colin J Henderson, et al.
The Journal of Biological Chemistry
|
September 16, 2005
Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding
Lesley A McLaughlin, Mark J I Paine, Carol A Kemp, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
March 3, 2011
Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model
Katerina Levová, Michaela Moserová, Vera Kotrbová, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 16, 2006
In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide
Jinglei Yu, Mark J I Paine, Jean-Didier Maréchal, et al.
Page
of 16
Search research articles
Search
Showing results (131-140 of 159) with videos related to
Sort By:
Page
of 16
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
September 24, 2011
Effect of hepatic cytochrome P450 (P450) oxidoreductase deficiency on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-DNA adduct formation in P450 reductase conditional null mice
Volker M Arlt, Rajinder Singh, Marie Stiborová, et al.
Cancer Research
|
May 6, 2004
Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines
Ruth L Stephen, Mattias C U Gustafsson, Morag Jarvis, et al.
The Biochemical Journal
|
March 3, 2004
Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite
Jack U Flanagan, Jean-Didier Maréchal, Richard Ward, et al.
Genes, Chromosomes & Cancer
|
October 20, 2005
Chromosomal changes in colorectal adenomas: relationship to gene mutations and potential for clinical utility
Amy Leslie, Arlene Stewart, David U Baty, et al.
Archives of Toxicology
|
January 26, 2018
Cytochrome b <sub>5</sub> impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b <sub>5</sub> /P450 reductase null (HBRN) mice
Lindsay Reed, Iveta Mrizova, Frantisek Barta, et al.
Toxicology
|
February 18, 2014
Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions
Marie Stiborová, Michaela Moserová, Věra Černá, et al.
Cancer Research
|
April 5, 2005
Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols
Volker M Arlt, Marie Stiborova, Colin J Henderson, et al.
The Journal of Biological Chemistry
|
September 16, 2005
Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding
Lesley A McLaughlin, Mark J I Paine, Carol A Kemp, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology
|
March 3, 2011
Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model
Katerina Levová, Michaela Moserová, Vera Kotrbová, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 16, 2006
In silico prediction of drug binding to CYP2D6: identification of a new metabolite of metoclopramide
Jinglei Yu, Mark J I Paine, Jean-Didier Maréchal, et al.
Page
of 16